These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22171470)

  • 81. What's next for an immuno-oncology powerhouse?
    Mullard A
    Nat Rev Drug Discov; 2021 Sep; 20(9):660-661. PubMed ID: 34389830
    [No Abstract]   [Full Text] [Related]  

  • 82. Proteomics-directed cloning of circulating antiviral human monoclonal antibodies.
    Sato S; Beausoleil SA; Popova L; Beaudet JG; Ramenani RK; Zhang X; Wieler JS; Schieferl SM; Cheung WC; Polakiewicz RD
    Nat Biotechnol; 2012 Nov; 30(11):1039-43. PubMed ID: 23138294
    [No Abstract]   [Full Text] [Related]  

  • 83. Editorial: the road to elimination of viral hepatitis-another promising real-world experience.
    Abdel-Daim MM
    Aliment Pharmacol Ther; 2020 Jul; 52(2):405-406. PubMed ID: 32592247
    [No Abstract]   [Full Text] [Related]  

  • 84. [VIRUSES, ANTIVIRAL DRUGS, LEUKEMIA, HEPATITIS, MESSAGE].
    SIRTORI C
    Gazz Sanit; 1965; 36():1-2. PubMed ID: 14339694
    [No Abstract]   [Full Text] [Related]  

  • 85. Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses.
    Wang Q; Huang Z
    Curr Opin Virol; 2022 Aug; 55():101247. PubMed ID: 35803202
    [No Abstract]   [Full Text] [Related]  

  • 86. [First observations on the treatment of some viral diseases by means of a new synthetic drug (xenalamine--C.V. 58903)].
    OLIVA G; SILVESTRI G
    Minerva Med; 1960 Jun; 51():2237-42. PubMed ID: 14428658
    [No Abstract]   [Full Text] [Related]  

  • 87. Measurement of the affinity of antiviral antibodies.
    Underwood PA
    Adv Virus Res; 1988; 34():283-309. PubMed ID: 3046256
    [No Abstract]   [Full Text] [Related]  

  • 88. [ON the problem of evaluation of the effectiveness of various preparations against virus diseases].
    Vopr Virusol; 1960; 5():121-2. PubMed ID: 13858445
    [No Abstract]   [Full Text] [Related]  

  • 89. Managing T2-high severe asthma in HIV-infected patients.
    Terl M; Jesenak M
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):1041-1043. PubMed ID: 33551031
    [No Abstract]   [Full Text] [Related]  

  • 90. Reply to "Managing T2-high severe asthma in HIV-infected patients".
    Curto E; Torrego A; Garin N; Crespo-Lessmann A; Plaza V
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):1043. PubMed ID: 33551032
    [No Abstract]   [Full Text] [Related]  

  • 91. [Antiviral humanized and human monoclonal antibodies].
    Lashkevich VA
    Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Respiratory syncytial virus: concerns and control.
    McCarthy CA; Hall CB
    Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
    [No Abstract]   [Full Text] [Related]  

  • 93. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
    Mitchell I
    South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
    [No Abstract]   [Full Text] [Related]  

  • 94. Antibodies for the prevention and treatment of viral diseases.
    Sawyer LA
    Antiviral Res; 2000 Aug; 47(2):57-77. PubMed ID: 10996394
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.